Public Health | Intellepedia

Cancerous Battle: Novartis and NATCO clash over Eltrombopag

In a landmark decision, the Delhi High Court overturned an injunction against Natco, allowing them to produce a generic version of Novartis’s cancer drug. The Court held that Novartis’s patent on a specific salt form of the drug (ELT-O) lacked novelty due to its coverage in an earlier patent (IN’176).

Intellectual Property, Accessibility and Public health

On the 30th of July 2020, the international organizations - WIPO, WTO and WHO jointly published a study report titled "Promoting access to medical technologies...

Coronavirus disease (COVID-19) advice for the public – World Health Organization (WHO)

BananaIP team is sharing the latest information provided by World Health Organization (WHO) on the COVID-19 outbreak, available on the WHO website. Most people who...

UNDP Issues Guidelines For Pharmaceutical Patent Examination

The UNDP has issued new guidelines aimed at strengthening pharmaceutical patent examination with an emphasis on public health. The guidelines advocate for stricter standards and the use of TRIPS flexibilities to curb evergreening and improve access to medicines.

Extension of Waiver for Pharma Patents until 2033 A.D.

The WTO has extended the waiver on pharmaceutical patent enforcement for least developed countries until 2033. This move ensures continued access to affordable generics from India and highlights the ongoing tension between patient access and patent rights.

Roche loses again

The Indian Patent Office has revoked Roche’s Valganciclovir patent, emphasizing Section 3d and public interest. This decision strengthens access to medicines in India and curbs evergreening by pharmaceutical companies.